Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain

  1. Rodríguez González-Moro, J.M. 2
  2. Menéndez, R. 3
  3. Campins, M. 7
  4. Lwoff, N. 5
  5. Oyagüez, I. 6
  6. Echave, M. 6
  7. Rejas, J. 4
  8. Antoñanzas, F. 1
  1. 1 Universidad de La Rioja
    info

    Universidad de La Rioja

    Logroño, España

    ROR https://ror.org/0553yr311

  2. 2 Hospital General Universitario Gregorio Marañón
    info

    Hospital General Universitario Gregorio Marañón

    Madrid, España

    ROR https://ror.org/0111es613

  3. 3 Hospital Universitario La Fe
    info

    Hospital Universitario La Fe

    Valencia, España

    ROR https://ror.org/01ar2v535

  4. 4 Health Economics and Outcomes Research Department, Pfizer SLU, Avda. de Europa, 20-B, Parque Empresarial La Moraleja, Alcobendas, Madrid, Spain
  5. 5 Medical Department, Pfizer SLU, Alcobendas, Madrid, Spain
  6. 6 Pharmacoeconomics and Outcomes Research Iberia, Madrid, Spain
  7. 7 Hospital Vall d'Hebron
    info

    Hospital Vall d'Hebron

    Barcelona, España

    ROR https://ror.org/03ba28x55

Revista:
Clinical Drug Investigation

ISSN: 1173-2563

Año de publicación: 2016

Volumen: 36

Número: 1

Páginas: 41-53

Tipo: Artículo

DOI: 10.1007/S40261-015-0345-Z SCOPUS: 2-s2.0-84946763314 WoS: WOS:000368144800003 GOOGLE SCHOLAR

Otras publicaciones en: Clinical Drug Investigation

Repositorio institucional: lock_openAcceso abierto Editor

Resumen

Background: Patients with chronic obstructive pulmonary disease (COPD) are at elevated risk of pneumococcal infection. A 13-valent pneumococcal conjugate vaccine (PCV13) was approved for protection against invasive disease and pneumonia caused by Streptococcus pneumoniae in adults. This study estimated the incremental cost-effectiveness ratio (ICER) of vaccinating COPD patients ≥50 years old with PCV13 compared with current vaccination policy (CVP) with 23-valent pneumococcal polysaccharide vaccine. Methods: A Markov model accounting for the risks and costs for all-cause non-bacteremic pneumonia (NBP) and invasive pneumococcal disease (IPD) was developed. All parameters, such as disease incidence and costs (€; 2015 values), were based on published data. The perspective of the analysis was that of the Spanish National Healthcare System, and the horizon of evaluation was lifetime in the base case. Vaccine effectiveness considered waning effect over time. Outcomes and costs were both discounted by 3 % annually. Results: Over a lifetime horizon and for a 629,747 COPD total population, PCV13 would prevent 2224 cases of inpatient NBP, 3134 cases of outpatient NBP, and 210 IPD extra cases in comparison with CVP. Additionally, 398 related deaths would be averted. The ICER was €1518 per quality-adjusted life-year (QALY) gained for PCV13 versus CVP. PCV13 was found to be cost effective versus CVP from a 5-year modelling horizon (1302 inpatient NBP and 1835 outpatient NBP cases together with 182 deaths would be prevented [ICER €25,573/QALY]). Univariate and probabilistic sensitivity analyses confirmed the robustness of the model. Conclusions: At the commonly accepted willingness-to-pay threshold of €30,000/QALY gained, PCV13 vaccination in COPD patients aged ≥50 years was a cost-effective strategy compared with CVP from 5 years to lifetime horizon in Spain. © 2015 The Author(s)